Independent · evidence-anchored·Reviewed by the GLPHelper Medical Team
EN·ES
glp·helper
Find a Provider →
glphelper.com/tirzepatide/tennessee/chattanooga
Dual GIP / GLP-1 receptor agonistFDA-approved May 2022 (Mounjaro) · November 2023 (Zepbound)Rx · Subcutaneous injection · Once weekly

Tirzepatide® providers &
prescriptions in Chattanooga, TN

Verified Tirzepatide providers in Chattanooga, TN. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

city providers
35
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: Tennessee
35 of 35 shown

Find a Tirzepatide provider in Tennessee.

Every entry is checked against the NPI registry and the Tennessee medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Tennessee city · /tirzepatide/tennessee/{city}
Knoxville
42 →
Nashville
36.16°N
35 →
Memphis
38 →
§ 03Getting Tirzepatide in Chattanooga
35 providers · Chattanooga, TN

How to get Tirzepatide in Chattanooga.

35 GLP-1 prescribers and 7 local resource types are on record for Chattanooga, plus 3 nearby towns in the directory.

Prescribers in Chattanooga
35 prescribers
35 GLP-1 prescribers in Chattanooga, most listed as Family Medicine (12), Internal Medicine, Endocrinology, Diabetes & Metabolism (11) and Internal Medicine (11). Any Tennessee-licensed physician, nurse practitioner, or PA can prescribe Tirzepatide, over video or in person. The nearest towns on record are Knoxville (42 providers), Nashville (35 providers) and Memphis (38 providers).
Around the prescription in Chattanooga
7 listed nearby
6 dietitians, 2 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 6 places to move are on record near Chattanooga.
Medicaid (weight loss)
Covered
As of April 2026, Tennessee Medicaid covers GLP-1s for weight loss, usually with prior authorization and BMI criteria, on top of the standard diabetes coverage. Employer and private plans vary; coverage is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Tennessee’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

The molecule in Mounjaro and Zepbound. It acts on two gut-hormone pathways, GIP and GLP-1.

Tirzepatide is a once-weekly injection sold by Eli Lilly as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management). It is the first approved dual GIP/GLP-1 receptor agonist. It activates two gut-hormone pathways rather than one, which is associated with greater average weight loss than single GLP-1 agonists.[2][3]

In SURMOUNT-1, adults with obesity (without diabetes) lost a mean of 20.9% of body weight on the 15 mg dose at 72 weeks, versus 3.1% on placebo. In the SURPASS-2 head-to-head diabetes trial, tirzepatide produced larger HbA1c and weight reductions than semaglutide 1 mg.[1]

At a glanceMultiple (brand-specific)
Generic name
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
May 2022 (Mounjaro) · November 2023 (Zepbound)
Approved use
Type 2 diabetes (Mounjaro) · chronic weight management (Zepbound)
Off-label use
Use outside the approved brand/indication is off-label
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in Tennessee

Diagnosed diabetes reaches 12.7% of adults in Tennessee.

of Tennessee adults have obesity
37.6%
diagnosed diabetes
12.7%

Age-adjusted estimates for Tennessee, community figures, not individual risk. CDC BRFSS 2023.

Estimate your weight lossmale-specific GLP-1 side effects
§ 05Support around Tirzepatide in Chattanooga
6 dietitians

The prescription is one part. Here is the rest, in Chattanooga.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Chattanooga, TN, ordered as the registry lists them, never by who pays us.

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Amir Alakaam, PhD. RDN
RD
Registered dietitian
518 Oak St Dept 6606
Call 423-425-4745NPI 1427691237
Mackenzie Allen, RD
RD
Registered dietitian
68 Middle River Rd Apt 248
Call 810-790-5301NPI 1386582302
Mary Allison, RD, LDN
RD
Registered dietitian
425 Cumberland St
Call 423-495-0167NPI 1457699910
Theresa Averbeck, R.D
RD
Registered dietitian · Renal
979 E 3Rd St
Call 423-778-7036NPI 1699808436
Malorie Bachofner, RDN, LDN
RD
Registered dietitian
6580 Kenton Ridge Cir
Call 847-887-9433NPI 1437916160
Rachel Baker, RDN, LDN
RD
Registered dietitian
7105 Crossroads Blvd Ste 102
Call 615-905-6029NPI 1497341267

Nutritionists

A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.

Rebecca Matherley, MS, RDN, LDN
NUTRITIONIST
Nutritionist
425 Cumberland St Ste 110
Call 423-698-0802NPI 1376230193
Peggy Noblett, R.D
NUTRITIONIST
Nutritionist
425 Cumberland St
Call 423-698-0802NPI 1134475908
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURMOUNT weight-management program and the SURPASS diabetes program, including the SURPASS-2 head-to-head against semaglutide. Figures are means at each trial's primary endpoint.

SURMOUNT-1 randomized 2,539 adults with obesity (without diabetes) across 72 weeks. Mean weight change was −15.0% (5 mg), −19.5% (10 mg), and −20.9% (15 mg) versus −3.1% with placebo. A majority of patients on the higher doses lost ≥20% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (15 mg)
−20.9%
SURMOUNT-1, 72 wk vs −3.1% placebo[2]
Mean weight change (5 mg)
−15.0%
SURMOUNT-1, 72 wk[2]
HbA1c reduction (T2D)
−1.8 to −2.6%
SURPASS program[4]
vs. semaglutide 1 mg
Superior
SURPASS-2, HbA1c + weight[3]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average tirzepatide weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
12 to 24%
mild
Dose-dependent; usually eases after titration
Diarrhea
12 to 19%
mild
More frequent during dose escalation
Vomiting
5 to 13%
mild
Reduced by slower titration
Constipation
6 to 17%
mild
Decreased appetite
5 to 11%
mild
Expected pharmacologic effect
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash, Zepbound (no insurance)
$1,000 to $1,300
per month
Brand-name retail; Lilly self-pay vials lower for some doses[6]
Cash, Mounjaro (no insurance)
$1,000 to $1,200
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Commercial insurance (weight)
Often denied
Zepbound is on-label but frequently requires PA
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Tirzepatide providers in Tennessee

NPI-verified Tirzepatide (tirzepatide) prescribers and clinics, ordered by availability, never by who pays us.

Weight loss doctors in Tennessee
Board-certified prescribers verified against the NPI registry.
Weight loss clinics in Tennessee
Clinics running GLP-1 programs, telehealth & in-person.
Tirzepatide in other states

Find NPI-verified Tirzepatide (tirzepatide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Tirzepatide in Alabama→Tirzepatide in Alaska→Tirzepatide in Arizona→Tirzepatide in Arkansas→Tirzepatide in California→Tirzepatide in Colorado→Tirzepatide in Connecticut→Tirzepatide in Delaware→Tirzepatide in Florida→Tirzepatide in Georgia→Tirzepatide in Hawaii→Tirzepatide in Idaho→Tirzepatide in Illinois→Tirzepatide in Indiana→Tirzepatide in Iowa→Tirzepatide in Kansas→Tirzepatide in Kentucky→Tirzepatide in Louisiana→Tirzepatide in Maine→Tirzepatide in Maryland→Tirzepatide in Massachusetts→Tirzepatide in Michigan→Tirzepatide in Minnesota→Tirzepatide in Mississippi→Tirzepatide in Missouri→Tirzepatide in Montana→Tirzepatide in Nebraska→Tirzepatide in Nevada→Tirzepatide in New Hampshire→Tirzepatide in New Jersey→Tirzepatide in New Mexico→Tirzepatide in New York→Tirzepatide in North Carolina→Tirzepatide in North Dakota→Tirzepatide in Ohio→Tirzepatide in Oklahoma→Tirzepatide in Oregon→Tirzepatide in Pennsylvania→Tirzepatide in Rhode Island→Tirzepatide in South Carolina→Tirzepatide in South Dakota→Tirzepatide in Tennessee→Tirzepatide in Texas→Tirzepatide in Utah→Tirzepatide in Vermont→Tirzepatide in Virginia→Tirzepatide in Washington→Tirzepatide in West Virginia→Tirzepatide in Wisconsin→Tirzepatide in Wyoming→
Related GLP-1 research
how tirzepatide titration works
Starting dose, step-ups, and the 2.5-to-15 mg ladder.
oral and sublingual GLP-1 options
Pills and drops vs injections: what the evidence supports.
§ 09Frequently asked: Tirzepatide in Tennessee

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Tirzepatide is the active molecule in both Eli Lilly products. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. They are the same drug with different approved indications, and insurers treat them as separate products.[1]